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Codelivery of a cytotoxin and photosensitiser via a
liposomal nanocarrier: a novel strategy for light-
triggered cytosolic release†
Elnaz Yaghini, *‡a Ruggero Dondi,‡b Karen J. Edler, c Marilena Loizidou, a
Alexander J. MacRobert *a and Ian M. Eggleston *b
Endosomal entrapment is a key issue for the intracellular delivery of many nano-sized biotherapeutics to
their cytosolic or nuclear targets. Photochemical internalisation (PCI) is a novel light-based solution that
can be used to trigger the endosomal escape of a range of bioactive agents into the cytosol leading to
improved eﬃcacy in pre-clinical and clinical studies. PCI typically depends upon the endolysosomal colo-
calisation of the bioactive agent with a suitable photosensitiser that is administered separately. In this
study we demonstrate that both these components may be combined for codelivery via a novel multi-
functional liposomal nanocarrier, with a corresponding increase in the biological eﬃcacy of the encapsu-
lated agent. As proof of concept, we show here that the cytotoxicity of the 30 kDa protein toxin, saporin,
in MC28 ﬁbrosarcoma cells is signiﬁcantly enhanced when delivered via a cell penetrating peptide (CPP)-
modiﬁed liposome, with the CPP additionally functionalised with a photosensitiser that is targeted to
endolysosomal membranes. This innovation opens the way for the eﬃcient delivery of a range of biother-
apeutics by the PCI approach, incorporating a clinically proven liposome delivery platform and using
bioorthogonal ligation chemistries to append photosensitisers and peptides of choice.
1. Introduction
The intracellular delivery of many promising biotherapeutics
and nanomedicines is often hampered by endosomal entrap-
ment.1 This can aﬀect many important protein therapeutics
and protein-targeted drugs,2 as well as emerging nucleic acid
therapeutics developed for gene therapy applications.3
Macromolecular therapeutics are typically taken up into the
cell by endocytic processes, whereupon they remain seques-
tered in endo/lysosomes, and are both prevented from reach-
ing their intracellular targets and are susceptible to degra-
dation by lysosomal enzymes.4 A number of approaches have
been investigated to facilitate the escape of entrapped thera-
peutics, such as the addition or coadministration of an endo-
some-disrupting agent with the entrapped material,5 however
a potentially much more flexible solution is one where escape
can be triggered by an external stimulus such as light.6,7
Photochemical internalisation (PCI)8,9 is a highly eﬀective
approach for eﬀecting endosomal release that relies upon the
light-based technique of photodynamic therapy (PDT).10 In
PCI, endosomal escape of the therapeutic agent may be trig-
gered with light after coadministration of a suitable photosen-
sitiser alongside the therapeutic agent. Provided that the
photosensitiser has the appropriate physical properties it may
localise in the endo/lysosomal membranes of the organelles
where the therapeutic agent is sequestered, and in this way,
upon irradiation the reactive oxygen species (ROS) that are gen-
erated induce selective damage and partial rupture of the orga-
nelles.11,12 This allows entrapped molecules to escape to reach
their intracellular targets, but the viability of the cells them-
selves is not compromised. The feasibility and safety of PCI
has recently been demonstrated in a clinical context for the
treatment of head and neck cancer using bleomycin, a hydro-
philic glycopeptide agent that is taken up into cells by endo-
cytosis and normally remains entrapped in endosomes.13
Preclinical studies with various therapeutic proteins and
protein toxins have also shown similar promise.14 A further
advantage of PCI compared to other methods of targeted drug
release is that it is both spatially and temporally selective,
which therefore also provides scope for novel applications in
biomedical research such as light-triggered gene silencing15
and immunotherapy.16
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Although a wide range of photosensitisers have been devel-
oped for PDT,17 only a limited sub-set actually possess the
correct properties for use in PCI. The key requirement for a
PCI photosensitiser is an amphiphilic character that not only
promotes its internalisation via endocytosis within the same
intracellular vesicle as a coadministered therapeutic, but cru-
cially also allows it to localise specifically in the hydrophobic
environment of the endosomal membranes.18,19 In this way,
selective oxidative damage to endosomal membranes can be
eﬀected upon irradiation so as to allow the escape of
entrapped agents and also the photosensitiser itself. Some of
the most eﬀective PCI photosensitisers to date which possess
the required intrinsic amphiphilic character are sulfonated
tetrapyrrole derivatives, such as the porphyrin, disulfonated
tetraphenylporphine (TPPS2a), and the disulfonated alu-
minium phthalocyanine, AlPcS2,
18 as well as the clinically used
disulfonated tetraphenyl chlorin derivative, fimaporfin.20 We
have however shown that the necessary amphiphilic and lyso-
somotropic properties can be engineered through the conju-
gation of otherwise highly hydrophobic photosensitisers to cat-
ionic cell-penetrating peptides (CPPs), to produce molecules
that not only have the desired properties for PCI, but are
superior to more classical tetrapyrrole-based derivatives.21,22
Other researchers have also adopted this principle of peptide-
targeting with other photoactivatable dyes,23–26 and in this
context, we recently demonstrated that CPP-conjugation can be
a very attractive way of repurposing well-known photosensiti-
sers that are clinically approved for PDT such as chlorin e6,
which lack the appropriate physical properties for PCI.27 This
could be easily achieved by the application of biorthogonal lig-
ation chemistry for the attachment of the chosen photosensiti-
ser to a readily available derivatised CPP, opening up the possi-
bility of using other clinical PDT photosensitisers with the
most attractive spectroscopic properties (i.e. strong absorption
in the red region) for PCI purposes.15,17
Liposome nanocarriers have received much attention for
the enhanced delivery of proteins and other biotherapeutics to
address issues of toxicity, stability and targeting.28–31 However,
despite considerable investigations into tailoring the lipid
composition of these systems,30 endosomal entrapment
remains a major barrier to eﬀective delivery. An additional
issue is that in order for encapsulated agents to exert their
eﬀects after internalisation, they must also escape the interior
of such nanocarriers,32 which ideally might be eﬀected in a
directed fashion by application of an external stimulus such as
heat or light.33,34 Fretz et al. have demonstrated that the endo-
somal entrapment of liposome systems may be overcome by
PCI using a conventional coadministered photosensitiser,35
and such studies have now led to considerable recent interest
in the development of light-triggered systems where a photo-
sensitiser is loaded into the liposome structure itself to eﬀect
the destabilisation of the bilayer membranes of both the endo-
lysosomes where the nanocarrier is entrapped15 and the lipo-
some nanocarrier itself.36–39 Although this meets the key
requirement for PCI of colocalisation of the photosensitiser
and entrapped agent, the eﬀectiveness of such systems
depends upon the localisation and orientation of a given
photosensitiser in the lipid bilayer of the carrier, with incor-
poration of the photosensitiser itself potentially having a sig-
nificant eﬀect on the stability of the liposomal formulation.40
In the present study we have explored whether a more flex-
ible and powerful strategy could be provided by an extension
of our CPP-conjugation approach for PCI, as outlined in
Scheme 1. The liposomal carrier within which a biomolecule
is encapsulated is labelled with CPP units, a certain proportion
of which are further functionalised with a hydrophobic por-
phyrin component connected to the peptide via a flexible
linker. We reasoned that in this way the photosensitiser would
be presented at the exterior surface of the liposome via the
hydrophilic CPP,41 independent of the precise nature of the
former, and as such would be able to eﬀectively access endo/
lysosomal membranes upon internalisation, providing the
required light-triggered escape device for PCI. At the same
time, as the photosensitiser is covalently tethered to the nano-
carrier, suﬃcient ROS-mediated damage of the liposome can
also be achieved to liberate the biomolecule to be delivered.
Further potential advantages of this carrier approach are the
possibility to eﬀect the highly controlled delivery of structu-
Scheme 1 Design and assembly of liposomal nanocarrier presenting an endolysosomally targeted photosensitiser at the surface for light-triggered
intracellular release of the liposomal cargo (cytotoxin).
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rally diverse molecules, including ones not normally subject to
endosomal entrapment,33,42,43 or where 1 : 1 encapsulation in
a suitable “Trojan horse”44 is not achievable.
As a proof of concept for such a modular delivery system,
we have incorporated a nano-sized protein toxin within such a
tailored liposomal system and examined the light-triggered




Chemical reagents for peptide synthesis and bioconjugations
were obtained from Sigma-Aldrich (Gillingham, UK) and
Novabiochem (Nottingham, UK). Peptide grade dimethyl-
formamide (DMF) was obtained from Rathburn Chemicals
(Walkerburn, UK). Anhydrous dichloromethane (DCM) was
obtained by distillation over calcium hydride. All other sol-
vents were obtained from Fisher Scientific (Loughborough,
UK) and used as received. HEPES buﬀer refers to a solution
that was 10 mM HEPES, 137 mM NaCl. DSPE-PEG2000 and
DSPE-PEG2000-maleimide were purchased from Nanocs Inc.
(New York, USA). EPC (egg phosphatidylcholine) and chole-
sterol were obtained from Sigma-Aldrich. Saporin from
Saponaria oﬃcinalis seeds was obtained from Sigma-Aldrich.
MC28 cells, a methylcholanthrene-induced rat fibrosarcoma
cell line, were grown in DMEM supplemented with 10% FCS at
37 °C in a humidified atmosphere containing 5% CO2.
Materials for the cell studies were purchased from Sigma-
Aldrich. Cellular uptake experiments were performed using a
fluorescence microplate reader (Fluoroskan Ascent PL,
Thermo Labsystems, Ireland). UV spectra were recorded on a
PerkinElmer Lambda 19 uv/vis spectrophotometer.
Fluorescence spectra were recorded on a Cary Eclipse fluori-
meter. Analytical RP-HPLC was performed on a Dionex
Ultimate 3000 system (Dionex, UK), with a VWD-3400 variable
wavelength detector. Analyses were performed at 35 ± 0.1 °C
on a Gemini 5 μ C18 110 A column, (150 × 4.6 mm –
Phenomenex, UK), equipped with a Security Guard C18 (ODS)
4 × 3.0 mm ID guard column (Phenomenex, UK), at a flow rate
of 1 mL min−1. Mobile phase A was 0.1% aq. TFA, mobile
phase B was 0.1% TFA in MeCN. (Gradient: 0.0–10.0 min
0–95% B, 10.0–20.0 min 95% B, 20.0–20.1 min at 95–5% B,
20.1–23.0 min 5% B.) Preparative RP-HPLC was performed on
a Dionex HPLC system equipped with a Phenomenex Gemini
5 μ C18 (250 × 10 w mm) column at a flow rate of 2.5 mL
min−1. High resolution mass spectrometry was performed
using a Bruker MicroTOF autospec ESI mass spectrometer.
Preparation of peptide derivatives
H-Gly-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Gly-Tyr-Lys-Cys-NH2 (1)
(Cys-CPP). The unlabelled Tat(48–57) derivative was syn-
thesised by Fmoc strategy as described previously.45
11-Azido-undecanoyl-Gly-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Gly-
Tyr-Lys-Cys(StBu)-NH2 (2). The synthesis of the ligatable Tat
(48–57) derivative was performed on 250 mg of resin
(0.15 mmol scale) by Fmoc strategy on Rink Amide MBHA
Resin (Novabiochem, 200–400 mesh, 0.60 mmol g−1 loading).
Removal of the Fmoc group from the resin was performed
manually at room temperature with 20% piperidine/DMF
(2.5 mL, 4 × 3 min), using a disposable plastic reactor (Grace
UK). Attachment of the first residue was performed according
to the method of Han et al., using a 1 h coupling with no pre-
activation and Fmoc-Cys(SStBu)-OH (4 eq.), HATU (4 eq.),
HOBt (4 eq.) and collidine (4 eq.). This was followed by an
acetylation step (Ac2O/DIPEA/DMF = 1/1/8, 2.5 mL, 1 ×
10 min). The rest of the peptide sequence was assembled on
an Activo P11 automated synthesiser, with subsequent Fmoc
deprotection steps being performed using 25% piperidine/
DMF (3 mL, 1 × 5 min, 1 × 10 min), and the chain elongation
steps being performed at 60 °C for 35 min using 3 eq. of each
Fmoc-protected amino acid (Fmoc-Arg(Pmc)-OH, Fmoc-Gln
(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)-OH or Fmoc-Gly-
OH), PyBOP (3 eq.) and DIPEA (6 eq.) in DMF (4 mL). Acylation
of the N-terminus was performed manually with 11-azido-
undecanoic acid (4 eq.) and a 5 min preactivation using HATU
(4 eq.), HOBt (4 eq.), and DIPEA (6 eq.) in DMF (4 mL). The
peptide resin was washed thoroughly with DMF and DCM,
then it was treated with TFA/TIS/H2O (95/2.5/2.5) for 3 h. The
resin beads were filtered oﬀ and the filtrate was evaporated to
a small volume and then added dropwise to cold anhydrous
Et2O. The precipitated material was collected by centrifu-
gation, washed twice with Et2O, dissolved in 1% aq. TFA, fil-
tered using a 0.2 µm syringe filter and the resulting solution
was purified by semi-preparative HPLC (see General Remarks).
The purified peptide was then freeze-dried to give 2 (52.4 mg,
11%) as a white powder. Rt HPLC: tR: 5.88 min; ESI-HRMS
+:
calcd for C79H150N37O16S2: 645.7162, found: 645.7169 [M + 3H]
3+.
Porphyrin–peptide conjugate (4). A solution of peptide 1
(25.9 mg, 8.17 µmol) and porphyrin derivative 322 (18.0 mg,
19.0 µmol) in DMSO (2 mL) was stirred at room temperature
overnight, shielded from light. The mixture was diluted with
1.0% aq. TFA and directly purified by semi-preparative HPLC.
This gave 4 as a dark green freeze-dried solid (21.2 mg, 63%).
HPLC tR: 7.86 min; UV-vis (0.1% aq TFA), nm: 436, 521, 557,
596, 654; ESI-HRMS+: calcd for C155H214N46O19S2 1030.2284;
found: 1030.2397 [M + 3H]3+.
Porphyrin–peptide conjugate (5) (Cys-CPP-PS). A nitrogen-
degassed solution of 4 (6.0 mg, 1.5 µmol) in 0.1 M aq
NH4HCO3 buﬀer (1 mL) was treated with a degassed solution
of DTT (4.6 mg, 30.0 µmol) 0.1 M aq NH4HCO3 buﬀer
(100 µL). The mixture was stirred for 2 h at room temperature,
shielded from light, then it was directly injected into semi-pre-
parative HPLC for purification. This gave 5 (5.8 mg, 98%) as a
dark-green freeze-dried powder. Rt HPLC: tR: 7.88 min;
ESI-HRMS+: calcd for C151H210N46O19S: 750.9145, found:
750.9192 [M + 4H]4+.
Alexa fluor-labelled saporin
Saporin was reconstituted using 10 mM HEPES buﬀer (2 mL,
135 mM NaCl, pH 7.4) and desalted using Amicon Ultra
Paper Nanoscale























































































(Ultra-15, MWCO 10 kDa) spin filters. For a typical labelling,
200 µL of saporin (5 mg mL−1 in HEPES buﬀer) was treated with
a solution of Alexa Fluor 488 isothiocyanate in DMSO (20 mM,
25 µL) and gently mixed for 1 h while shielded from light. Excess
dye was removed by spin filtering and the labelled saporin was
diluted to 1 mL for a final concentration of 1 mg mL−1.
Preparation and characterisation of liposomes
Preparation of liposomes. For a typical preparation, EtOH
stock solutions containing EPC (14.2 mg, 16.7 µmol), chole-
sterol (7.7 mg, 20.0 µmol), DSPE-PEG2000 (0.69 mg, 0.25 µmol),
and DSPE-PEG2000-maleimide (0.46 mg, 0.16 µmol) respect-
ively were combined and the mixture was evaporated first with
a rotavapor, then under high-vacuum to form a lipid film. The
film was then hydrated using HEPES buﬀer (1 mL, or 1 mL of
1 mg mL−1 saporin in HEPES buﬀer for saporin-loaded lipo-
somes), heated at 60° C for 10 min and vortexed to form the
liposomes. The liposomes were then sized 41 times using
200 nm polycarbonate filters at 70° C in an Avanti Polar Lipids
miniextruder. The liposomes were purified to remove non-
encapsulated saporin by chromatography on Sepharose CL-4B,
and eluted with HEPES buﬀer.
Surface conjugation. A purified suspension of liposomes
(1 mL) was treated at 4° C with a solution of peptide 1 (0.8 mg,
0.21 µmol) in DMSO (29.6 µmol) and a solution of porphyrin–
peptide conjugate 5 (0.2 mg, 0.05 µmol) in DMSO (40 µL). The
liposomes were then incubated at 4° C for 18 h and purified to
remove excess unconjugated peptides by chromatography on
Sepharose CL-4B and eluted with HEPES buﬀer.
Characterisation. Liposome size was characterised by
Dynamic Light Scattering using a Malvern Zetasizer Nano.
Liposome preparations were sampled twice and each sample
as measured in triplicate and the results were averaged. Only
one peak was observed in both intensity and volume distri-
butions. Saporin-loaded TPP–Tat liposomes were determined
to have a diameter = 180 nm and polydispersity index 0.161.
The concentrations of photosensitiser and saporin were deter-
mined by analogy with the method of Sardan et al.46 and Oh
et al.47 (see ESI†).
Cellular uptake studies
MC28 cells were seeded in 96-well plates overnight with 5000
cells per well. The cells were then incubated with the por-
phyrin–peptide-conjugated liposomes without encapsulated
saporin (empty liposomes) and liposomes containing saporin
for 24 h or 48 h. After incubation, the cell medium was
removed, cells were washed with PBS and PBS (100 µL) was
added into each well. The intracellular levels of the peptide–
porphyrin conjugate following uptake of the liposomes were
assessed using the fluorescence of the porphyrin following
excitation at 405 nm and fluorescence was detected at 650 nm.
All experiments were performed in triplicate.
In vitro PDT and PCI
MC28 cells were seeded in 96-well plates for 24 h with 3000
cells per well. The medium was then removed and replaced
with fresh medium containing increasing concentrations of
empty liposomes or saporin-containing liposomes for 24 h.
For PDT (empty liposomes), the concentrations used were 25,
50 and 100 nM. For the PCI combination therapy (saporin-con-
taining liposomes), the respective concentrations of porphyrin
and saporin (in parentheses) used in nM were 25 (2.8), 50 (5.8)
and 100 (11.4). Control studies were also carried out using
liposomes containing saporin, but with surface conjugation
with peptide 1 alone, i.e. no attached porphyrin moiety. In all
cases, following incubation with the liposome samples, the
cell medium was removed, the cells were washed thoroughly
with PBS, then fresh full medium without the liposomes was
added and the cells were finally incubated for 4 h prior to
illumination. Illumination was carried out for up to 5 min
using a blue LumiSource® flatbed lamp with peak emission at
420 nm and 7 mW cm−2 output (PCI Biotech, Oslo, Norway).
Cell viability was evaluated at either 48 or 96 h after light illu-
mination using the standard MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay. All experiments were
performed in triplicate. Control groups with no drugs added
and with or without light were also assessed.
Subcellular localisation
For confocal microscopy MC28 cells were seeded in cover
glass-bottomed dishes (Fluorodish, World Precision Inst. UK),
at a density of 4000 cells per dish for 24 h. The cells were then
incubated with the saporin-containing liposomes (2 µM por-
phyrin concentration) for 24 h. For these imaging experiments,
the saporin was labelled with Alexa Fluor 488 as described
above. The cell medium was removed, and the cells were then
washed with PBS, resuspended with fresh phenol red-free
medium, and imaged using an Olympus Laser scanning con-
focal microscope (FluoView FV1000, 60× magnification, NA
1.20, Olympus UK Ltd, Essex, UK). Fluorescence from the por-
phyrin was recorded within the range of 620–720 nm using a
405 nm laser for the excitation. Control images were recorded
after 24 h incubation with empty TPP-Tat liposomes at the
same porphyrin concentration to confirm the absence of any
autofluorescence contribution in the Alexa Fluor detection
channel since the porphyrin also absorbs at 488 nm. For Alexa
Fluor 488 fluorescence imaging, cells were illuminated at
488 nm and the fluorescence signal was recorded at
510–560 nm. Image analysis and processing of the 16-bit
images were performed with ImageJ software.
Light-induced intracellular redistribution
MC28 cells were seeded in cover glass-bottomed dishes
(Fluorodish, World Precision Inst. UK), at a density of 4000
cells per dish for 24 h. The cells were then incubated with
Alexa Fluor-labelled saporin-containing liposomes (2 µM por-
phyrin concentration) for 24 h, and on-stage illumination at
405 nm was performed. An intial image of the Alexa Fluor fluo-
rescence was recorded as described above and then further
images were recorded at set delays up to 2 minutes following
on-stage illumination for 60 s at 405 nm, where the porphyrin
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absorbs strongly, in order to induce redistribution of the
labelled saporin.
Statistical analysis
Data were analysed using two-tailed Student’s T-test with
appropriate post hoc testing using Prism 6 software. Error bars
from the mean show ± standard deviation (SD). Values of P <
0.05 were considered to be statistically significant. Synergistic
cell-killing upon PCI was assessed using the following
equation to calculate the value of alpha (α):
α ¼ FPDT  Fcytotoxin
Fcombination
where F is the fractional viability for each separate therapy (i.e.
PDT and the application of the cytotoxin), and the denomi-
nator is the fractional viability observed following the PCI com-
bination treatment. If α > 1 then a synergistic eﬀect is
observed; α < 1 denotes an antagonistic eﬀect.48
3. Results and discussion
Synthesis of targeted liposomes
The coupling of cell penetrating peptides such as Tat (48–57)
to the outer surface of liposome particles is a well-established
principle for enhancing the translocation of such drug-carry-
ing materials across cell membranes.35,49–52 Building on our
previous studies with CPP-conjugated photosensitisers,21,22
the novel aspect of our nanocarrier approach for PCI (see
Scheme 1) is that the photosensitiser moiety that provides an
endosomal escape trigger is covalently linked to the carrier in
a highly predictable fashion via such a CPP. This ensures that
the photosensitiser can intercalate eﬀectively into the lipid
bilayer of endosomal membranes to eﬀect oxidative damage
and membrane disruption upon irradiation. Moreover, the
design provides a simple means to control the photosensitiser
loading and distribution over the carrier surface.
Liposomes were prepared by solvent evaporation/
hydration52 using egg-derived phosphatidylcholine (EPC) with
1.1 mol% PEG2000DSPE (0.4 mol% of PEG chains terminated
with a maleimide group). They were then surface functiona-
lised via thiol-maleimide ligation53,54 with peptide 1, a
C-terminally extended version of the Tat (48–57) peptide
sequence described by Santra et al.,55 and the related peptide
5 which was additionally labelled at the N-terminus with a tet-
raphenylporphyrin photosensitiser. Liposomes prepared as
above were also loaded with the 30 kDa ribosome-inactivating
protein, saporin, tagged with an independent fluorescent label
(Alexafluor 488). Saporin and related conjugates has been
extensively studied in a range of PCI investigations, both
in vitro and in vivo. It is taken up by endocytosis and exten-
sively trapped in endosomes, which thus provides an excellent
model for the delivery of poorly absorbed nano-sized thera-
peutics that may benefit from PCI technology.9
As outlined in Scheme 1, the maleimide-functionalised
DSPE component of the liposomes provides a thiol-reactive
handle for the attachment of the Cys-containing Tat peptide
units 1 and 4. The preparation of the targeting peptides 1 and
4 is shown in Scheme 2. Peptide 1 (Cys-CPP) was synthesised
as described previously by us45 by Fmoc solid phase peptide
synthesis on Rink amide MBHA resin, with trityl protection on
the Cys side chain, and with cleavage from the resin and
Scheme 2 Preparation of targeting peptides 1 and 5. The unlabelled Tat peptide 1 corresponds to the “Cys-CPP” unit in Scheme 1, while peptide 5
which is labelled at the N-terminus with a porphyrin photosensitiser corresponds to the “Cys-CPP-PS” unit.
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global deprotection being eﬀected with TFA/TIPS/EDT. For
peptide–porphyrin conjugate 5 (Cys-CPP-PS) the peptide
sequence was first assembled with incorporation of the
cysteine residue as Cys(StBu), and the N-terminus was acylated
on resin with 11-azidoundecanoic acid. Cleavage from the
resin with TFA/TIPS/H2O provided the intermediate azidopep-
tide 2 which was then combined with the ligatable tetraphenyl-
porphyrin derivative 322 (2 eq.) via strain-promoted azide–
alkyne cycloaddition (SPAAC)56 to give the bifunctional conju-
gate 4 in 63% yield following HPLC isolation (Scheme 2).
Finally, the Cys residue of 4 was selectively unmasked by
reduction using DTT to give 5 which was able to undergo a
second bioconjugation with the maleimide-bearing liposome
surface.
The final targeted nanocarriers were characterised by DLS
and UV/VIS absorbance and fluorescence spectroscopy. No sig-
nificant perturbation of the porphyrin emission spectrum was
observed for the labelled liposomes (see ESI†), consistent with
the presentation of the photosensitiser unit on the exterior of
the nanocarrier, rather than embedded in the lipid phase.53
Consistent with this observation, for saporin-loaded TPP–Tat
liposomes with diameter 180 nm, the number of pendant
porphyrins per liposome can be estimated to be ca. 250, with
an average linear separation of 20 nm,57 such that any neigh-
bour-to-neighbour self-quenching interactions should be
negligible.58
Cellular uptake and localisation
The relative uptake of the peptide-conjugated liposomes with
and without encapsulated saporin was examined in MC28 rat
fibrosarcoma cells by measuring the cellular fluorescence of
the surface-attached porphyrin photosensitiser, as shown in
Fig. 1. Two incubation times were compared, 24 and 48 h, and
three diﬀerent doses.
The porphyrin fluorescence increased versus the dose for
both incubation times and no significant diﬀerences were
observed in porphyrin cellular fluorescence values between
TPP–Tat liposomes with or without saporin. We could there-
fore conclude that the PDT eﬃcacy of each preparation should
be comparable without taking saporin cytotoxicity into
account. At porphyrin concentrations of 50 or 100 nM, the
fluorescence levels observed after 48 h incubation were only
marginally higher than those at 24 h, hence the shorter incu-
bation time was adopted for subsequent PDT/PCI studies.
As noted above, the modification of liposome carriers with
CPP has been widely used to enhance their uptake across cell
membranes, and where Arg-rich CPP such as Tat(48–57) are
employed this typically results in uptake of the nanocarrier via
endocytic processes and subsequent entrapment in endo-
somes.59,60 In this context, Fretz et al.50 have previously
demonstrated that Tat-modified liposomes are taken up via
endocytosis, with the localisation in endosomal compartments
being revealed by fluorescent labelling of one of the lipid
components.
In order to verify that our nanocarrier system provided the
desired subcellular colocalisation of saporin and the associ-
ated photosensitiser upon internalisation, and before
irradiation, we compared the intracellular distribution of the
porphyrin moiety and encapsulated Alexa Fluor-labelled
saporin using confocal fluorescence microscopy. Fig. 2A and B
show that there is a punctate subcellular localisation for both
the porphyrin (red) and saporin (green) fluorescence respect-
ively, which is coincident when merged in Fig. 2C, thus con-
firming that our strategy should provide the optimum physical
colocalization of photosensitiser and bioactive agent in the
same subcellular compartment required for eﬀective PCI.
Additional control images, 2D and E, recorded after incubation
with empty TPP–Tat liposomes confirm the presence of por-
phyrin signal but the absence of any autofluorescence contri-
bution in the Alexa Fluor detection channel.
Fig. 3A and B show sequential images of the eﬀect of pro-
longed on-stage illumination using the confocal microscope
405 nm laser on the intracellular fluorescence of the liposome-
encapsulated saporin labelled with Alexa Fluor. Acquisition of
Fig. 3A used an exposure time of only 1 s, which did not result
in detectable perturbation of the nascent fluorescence distri-
bution. However, after a further 60 s of on-stage exposure to
the laser a repeat image scan (with a 1 s exposure), recorded 60
s after the 405 nm illumination had ended, showed that the
initial punctate intracellular fluorescence had partly dispersed
and was consequently weaker (Fig. 3B). This dispersal of fluo-
rescence is consistent with the PCI mechanism whereby the
membranes of the endo/lysosomes harbouring the labelled
saporin are disrupted following illumination, allowing the bio-
molecule to redistribute freely. If the endo/lysosome is rup-
tured then the maxima of the fluorescence intensities in an
area containing these vesicles will decline since the dye is
spread over a larger volume and is no longer localised in a con-
fined site. These images also correspond well to those pre-
viously obtained by us using a very similar illumination proto-
col using a Tat–peptide–porphyrin conjugate that was adminis-
tered separately from fluorescently-labelled saporin.21
Fig. 1 In vitro cellular porphyrin ﬂuorescence levels of liposome conju-
gates in MC28 cells. Cells were incubated with TPP–Tat liposome conju-
gates or TPP–Tat–saporin liposome conjugates at various concen-
trations (25, 50, and 100 nM) for 24 h and 48 h. Porphyrin ﬂuorescence
was recorded at 650 nm using excitation at 410 and values in arbitrary
units (a.u.) are shown after subtraction of baseline levels measured in
control cells without addition of liposomes.
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The phototoxicity of the porphyrin–peptide-conjugated lipo-
somes without encapsulated saporin, was examined in MC28
cells following 24 h incubation, as shown in Fig. 4, as a func-
tion of concentration and illumination time. The dose–
response was assessed in terms of the total porphyrin photo-
sensitiser concentration (present in the solution) versus con-
trols without liposome addition, and dark values (i.e. without
illumination), with the range of concentrations and illumina-
tion times being based on previous studies by us with “stand
alone” Tat–peptide porphyin derivatives.21,22 Significant photo-
toxicity was observed with the empty liposomes which scaled
with higher photosensitiser concentration and light doses,
and at the highest concentration of 400 nM, cell viability was
significantly reduced to 7.4 ± 0.9% using 5 min illumination,
while at 50 nM, the viability was 53 ± 5%. Control experiments
in the dark showed that there was negligible dark toxicity at
concentrations considerably greater than those employed for
the PCI experiments (see below).
We have previously reported the phototoxicity of the Tat–
peptide–porphyrin derivative 622 in MC28 cells using the same
blue light source. This conjugate is a direct analogue of the
surface functionalisation structure present in the liposomes in
this study, with the N-terminus of the Tat (48–57) sequence
attached to the same porphyrin moiety via an identical ali-
phatic spacer and triazole linkage. Significantly, in the study
with 6, very similar phototoxicity values were observed at 48 h
following illumination compared to those obtained with the
liposome system here. This supports our hypothesis that such
peptide–photosensitiser units displayed on the exterior surface
of a liposomal carrier should be able to deliver an eﬀective
membrane-damaging eﬀect and endosomal escape.
Photochemical Internalisation studies (PCI)
Following on from the PDT studies, saporin-encapsulated lipo-
somes prepared as above were evaluated in MC28 cells for
light-triggered PCI enhancement of saporin cytotoxicity.
Saporin has been much used as a model nano-sized agent for
PCI studies (diameter: ca. 2 nm; MW: ca. 30 kDa) as it is prone
to entrapment and degradation within lysosomes following
endocytosis, thus severely restricting its cytotoxicity when
administered directly.35 Since PCI is designed to function at
sub-lethal PDT doses, the optimum porphyrin concentration
and light doses were first established using modified lipo-
somes without saporin (empty liposomes). Fig. 5A shows that
for porphyrin concentrations at 25–100 nM, a sub-lethal PDT
eﬀect with a loss of viability of ca. 50% was achieved for all
illumination times; for 100 nM the reduction of viability at
5 minutes was larger but still within the range applicable for
PCI. It should be noted once more, that at these concen-
trations, the TPP–Tat liposomes alone elicit no significant tox-
icity in the absence of light.
Based on these results, we proceeded to test liposomes for
PCI with these TPP–Tat concentrations. The same liposomal
conjugates with saporin (corresponding concentrations of 2.8,
5.8 and 11.4 nM) elicited only a small reduction in viability of
ca. 10% without illumination, as shown in Fig. 5B. In contrast,
after illumination the viabilities measured for the liposomal
Fig. 2 Cellular uptake of TPP–Tat–Saporin–Alexa Fluor 488 liposomal conjugate in MC28 cells using laser scanning confocal microscopy. Cells
were incubated with the conjugate for 24 h. Red colour in (A) represents the porphyrin ﬂuorescence signal from TPP–Tat (excitation: 405 nm).
Green colour in (B) represents the ﬂuorescence signal from Saporin–Alexa Fluor 488 (excitation at 488 nm). C: Merged image of A and B; D: por-
phyrin ﬂuorescence from empty TPP–Tat liposomes (excitation at 405 nm). E: control image of same ﬁeld as D with empty TPP–Tat liposomes (exci-
tation at 488 nm and detection at 510–560 nm). All images on same scale; scale bar: 10 μm.
Fig. 3 Cellular uptake and photo-induced redistribution of saporin–
Alexa Fluor 488 liposomal conjugate in MC28 cells (A) before light illu-
mination, (B) after light illumination using 405 nm laser for the exci-
tation. Middle arrow highlights an area where the Alexa Fluor ﬂuor-
escence is initially punctate (A) and transitions to a more diﬀuse distri-
bution (B); top and bottom arrows highlight bright spots of ﬂuorescence
that are absent after illumination due to dilution of the ﬂuorescence.
Each ﬁgure is from the same ﬁeld and confocal plane. Scale bar: 10 μm.
Light illumination on-stage was eﬀected for 60 s and the image was
recorded after a further 60 s delay.
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Fig. 4 PDT eﬀect of TPP–Tat–peptide liposome conjugation in MC28 cells after incubation for 24 h. Cells were incubated with the nanocarrier at
various concentrations and were illuminated either for 1.5, 3 or 5 min. MTT assay was carried out 48 h after light exposure. Data are presented as
mean value ± standard deviation (SD). The TPP–Tat–peptide unit conjugated to the liposome surface is directly related to Tat–peptide–porphyrin
derivative 6, previously studied as a stand-alone photosensitiser for PCI.22
Fig. 5 Light-induced cytotoxic response of liposome conjugates in MC28 cells, showing (A) PDT (TPP–Tat liposome conjugates without saporin),
(B) PCI (liposome conjugates containing both TPP–Tat and saporin), and (C) Tat conjugates with saporin but without TPP. Cells were incubated with
various concentrations of nanocarrier and saporin (TPP–Tat/Tat: 25, 50, and 100 nM, saporin: 2.8, 5.7, and 11.4 nM) and were illuminated for up to
5 minutes. MTT assay was carried out 96 h after light exposure. Data are presented as mean value ± standard deviation (SD) of three independent
experiments. *** shows signiﬁcance P < 0.0001 relative to control cells without liposomes.
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conjugates with saporin were significantly reduced. In Fig. 5C,
viability measurements are shown for cells incubated with the
Tat-conjugated liposomes containing saporin at the same con-
centrations and the same illumination conditions but without
porphyrin conjugation. From Fig. 5B, it can be seen that PCI
treatment resulted in significant reductions in viability using 3
or 5 min illumination, e.g. using 100 nM TPP and 11.4 nM
saporin (P < 0.0001). At these concentrations for the loaded
nanocarrier, the combined treatment reduced viability signifi-
cantly to 8.8% at 3 min illumination, compared to 91 ± % via-
bility without illumination. For PDT alone at 100 nM TPP, the
viability was 77 ± % (see Fig. 5A). Using the combination of 50
nM TPP and 3 min illumination and 5.7 nM saporin, the
overall reduction in viability was lower giving a value of 14.9 ±
% but still very significant. Thus, the combined PCI treatment
was significantly more eﬀective than the eﬀect of either liposo-
mal saporin or PDT with the empty porphyrin-labelled nano-
carrier, consistent with light-triggered release of saporin from
endosomes and intracellular relocalisation. Compared to treat-
ment with liposomal saporin alone, PCI reduced the cellular
viability by over an order of magnitude.
Fig. 5C further emphasises the eﬃcacy of our PCI strategy.
Here, the experiments of Fig. 5B were recapitulated using Tat-
modified liposomes with no porphyrin labelling. It can be
seen that in this case that at all concentrations of the saporin-
loaded nanocarrier and all light doses, the cellular toxicity is
minimal (ca. 95% viability). Thus in the absence of the escape
device provided by the porphyrin moiety, the nano-sized toxin
remains essentially completely entrapped in endosomes.
The relative synergistic eﬀects achieved via light-triggered
endosomal escape can be quantified, by the parameter α.48
This is derived from the fractional cellular viability determined
separately upon combined PCI treatment for a given thera-
peutic, the viability observed for direct administration of the
therapeutic alone, and the viability resulting from the PDT
eﬀect of a coadministered photosensitiser (see Experimental
section). Synergistic eﬀects are indicated by an α value signifi-
cantly greater than unity, whereas if the eﬀect of direct admin-
istration and PDT is merely additive, a value of α = 1 should be
observed. For the results in Fig. 5B, the best eﬀect was
achieved with codelivery of 100 nM TPP and 11.4 nM saporin,
with an illumination time of 3 min, which gave a value of α =
8.0. For comparison, using 50 nM TPP and 5.7 nM saporin for
the same illumination time gave a value of α = 4.7.
All other nanocarrier–saporin combinations also delivered
PCI synergistic eﬀects on cell viability (see Fig. 6) with the
associated combinations of photosensitiser and toxin compar-
ing favourably with those used to achieve similar in vitro
results when the latter was administered separately with Tat–
peptide conjugates bearing the hydrophobic TPP moiety at the
N- or C-terminus,21,22 or a conventional disulfonated tetraphe-
nylporphine derivative.21 It is encouraging to note that the α
values are higher (i.e. higher synergicity) using the liposomal
coadministration method than obtained in our previous study
in the same cell line22 where we administered a porphyrin–
peptide conjugate analogous to that used here and saporin
separately (α = 8 vs. α = 3.5).
When the viability measurements were carried out at 48 h
(Fig. 6) after light treatment instead of 96 h, a synergistic PCI
eﬀect was also observed, albeit with lower α values: codelivery
of 100 nM TPP and 11.4 nM saporin with an illumination time
of 3 min gave 3.4 for α compared to 8 at 96 h. The PCI-induced
reduction in viability was also lower at 48 h. The higher
eﬃcacy observed at 96 h compared to 48 h reflects the slower
onset of the cytotoxic action of released saporin via apoptosis
and is consistent with our own previous results61 and other
PCI studies.62
4. Conclusions
Endosomal entrapment is a major current issue for the
eﬀective delivery of nanomedicines. In this study we have
demonstrated that cytosolic delivery of a macromolecule that
is normally subject to endosomal entrapment can be achieved
via a liposomal nanocarrier that is functionalised so as to
codeliver a membrane-localising photosensitiser for a highly
eﬃcient PCI eﬀect. This approach thus simultaneously avoids
the practical disadvantage of current PCI protocols whereby
the photosensitiser and drug are administered separately,
Fig. 6 Light-induced cytotoxic response of liposome conjugates in MC28 cells, showing (A) PDT (TPP–Tat liposome conjugates without saporin)
and (B) PCI (liposome conjugates conjugates containing both TPP–Tat and saporin) eﬀects. Cells were incubated with various concentrations of
TPP–Tat and saporin (TPP–Tat: 25, 50, and 100 nM, saporin: 2.8, 5.7, and 11.4 nM) and were illuminated for up to 5 min. MTT assay was carried out
48 h after light exposure. Data are presented as mean value ± standard deviation (SD) of three independent experiments. *** shows signiﬁcance P <
0.0001.
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while also enabling eﬀective targeting of the photosensitiser
towards the endosomal membrane via the peptide component.
Unlike other nanocarrier-based approaches, our strategy pro-
vides the flexibility to easily vary the loading of the drug to be
delivered, while keeping the same level of surface photosensiti-
ser. Moreover, our approach using liposomes as the nano-
carrier enables the use of macromolecular drugs as well as
small molecule drugs, or even combinations thereof. The
modular assembly of the liposomal system also oﬀers scope
for the straightforward incorporation of alternative CPPs with
inherent tumour-homing properties, as well as other photo-
sensitiser moieties which absorb in the NIR. This should oﬀer
a versatile strategy for the targeted and minimally invasive
delivery of a range of poorly absorbed therapeutic agents with
high potential for clinical translation.
Conﬂicts of interest
There are no conflicts to declare.
Acknowledgements
This work was supported by BBSRC grants BB/J009164/1 (IME)
and BB/J009318/1 (AJM) at Bath and UCL respectively.
References
1 P. Lonn, A. D. Kacsinta, X.-S. Cui, A. S. Hamil, M. Kaulich,
K. Gogoi and S. F. Dowdy, Sci. Rep., 2016, 6, 32301.
2 A. Fu, R. Tang, J. Hardie, M. E. Farkas and V. M. Rotello,
Bioconjugate Chem., 2014, 25, 1602–1608.
3 S. F. Dowdy, Nat. Biotechnol., 2017, 35, 222–229.
4 A. K. Varkouhi, M. Scholte, G. Storm and H. J. Haisma,
J. Controlled Release, 2011, 151, 220–228.
5 K. K. Hou, H. Pan, P. H. Schlesinger and S. A. Wickline,
Biotechnol. Adv., 2015, 33, 931–940.
6 G. Shin, S. Ko, D. Kim, Q.-V. Lee, G. T. Park, J. Lee,
T. Kwon, H.-G. Choi, Y. B. Kim and Y.-K. Oh, J. Controlled
Release, 2017, 267, 67–79.
7 Y. Lee and D. H. Thompson, Nanomed. Nanobiotechnol.,
2017, 9, 1–40.
8 K. Berg, A. Weyergang, L. Prasmickaite, A. Bonsted,
A. Høgset, M. T. R. Strand, E. Wagner and P. K. Selbo,
Methods Mol. Biol., 2010, 635, 133–145.
9 B. A. Martinez de Pinillos, C. M. Moore, M. Loizidou,
A. J. MacRobert and J. H. Woodhams, Int. J. Cancer, 2016,
138, 1049–1057.
10 A. P. Castano, T. N. Demidova and M. R. Hamblin,
Photodiagn. Photodyn. Ther., 2004, 1, 279–293.
11 I. Meerovich, N. Muthukrishnan, G. A. Johnson, A. Erazo-
Oliveras and J.-P. Pellois, Biochim. Biophys. Acta, 2014, 1840,
507–515.
12 T.-Y. Wang, M. D. J. Libardo, A. M. Angeles-Boza and
J.-P. Pellois, ACS Chem. Biol., 2017, 12, 1170–1182.
13 A. A. Sultan, W. Jerjes, K. Berg, A. Høgset, C. A. Mosse,
R. Hamdoudi, Z. Hamdoon, C. Simeon, D. Carnell,
M. Forster and C. Hopper, Lancet Oncol., 2016, 17, 1217–
11229.
14 P. K. Selbo, M. Bostad, C. E. Olsen, V. T. Edwards,
A. Høgset, A. Weyergang and K. Berg, Photochem. Photobiol.
Sci., 2015, 14, 1433–1450.
15 W. Chen, W. Deng and E. M. Goldys, Mol. Ther.–Nucleic
Acids, 2017, 7, 366–377.
16 C. Bruno, Y. Waeckerle-Men, M. Håkerud, T. M. Kündig,
B. Gander and P. Johansen, J. Immunol., 2015, 195, 166–173.
17 H. Abrahamse and M. R. Hamblin, Biochem. J., 2016, 473,
347–364.
18 K. Berg, P. K. Selbo, L. Prasmackaite, T. E. Tjelle,
K. Sandvig, D. Moan, G. Gaudernack, O. Fodstad,
S. Kjolsrud, H. Anholt, G. H. Rodal, S. K. Rodal and
A. Høgset, Cancer Res., 1999, 59, 1180–1183.
19 V. S. Gaware, M. Hakerud, K. Leosson, S. Jonsdottir,
A. Høgset, K. Berg and M. Masson, J. Med. Chem., 2013, 56,
807–819.
20 J. T.-W. Wang, K. Berg, A. Høgset, S. G. Bown and
A. J. MacRobert, Photochem. Photobiol. Sci., 2013, 12, 519–
526.
21 J. T.-W. Wang, F. Giuntini, I. M. Eggleston, S. G. Bown and
A. J. MacRobert, J. Controlled Release, 2012, 157, 305–313.
22 R. Dondi, E. Yaghini, K. M. Tewari, L. Wang, F. Giuntini,
M. Loizidou, A. J. MacRobert and I. M. Eggleston, Org.
Biomol. Chem., 2016, 14, 11488–11501.
23 N. Muthukrishnan, S. Donovan and J.-P. Pellois,
Photochem. Photobiol., 2014, 90, 1034–1042.
24 T. Ohtsuki, S. Miki, S. Kobayashi, T. Haraguchi, E. Nakata,
K. Hirakawa, K. Sumita, K. Watanabe and S. Okazaki, Sci.
Rep., 2015, 5, 18577.
25 C.-K. Park, Y. H. Kim, S. Hwangbo and H. Cho,
Int. J. Nanomed., 2017, 12, 8185–8196.
26 R. Yarani, T. Shirashi and P. E. Nielsen, Sci. Rep., 2018, 8,
638.
27 E. Yaghini, R. Dondi, K. M. Tewari, M. Loizidou,
I. M. Eggleston and A. J. MacRobert, Sci. Rep., 2017, 7,
6059.
28 M. Ray, Y. W. Lee, F. Scalleti, R. J. Yu and V. M. Rotello,
Nanomedicine, 2017, 12, 941–952.
29 Z. Gu, A. Biswas, M. Zhao and Y. Tang, Chem. Soc. Rev.,
2011, 40, 3638–3655.
30 S. Patel, N. Ashwanikumar, E. Robinson, A. DuRoss,
C. Sun, K. E. Murphy-Benenato, C. Mihai, O. Almarsson
and G. Sahay, Nano Lett., 2017, 17, 5711–5718.
31 Z. Drulis-Kawa and A. Dorotkiewicz-Jach, Int. J. Pharm.,
2010, 387, 187–198.
32 S. Itakura, S. Hama, T. Oghita and K. Kogure, PLoS One,
2014, 9, e111181.
33 T. Fuse, T. Tagami, M. Tane and T. Ozeki, Int. J. Pharm.,
2018, 540, 50–56.
34 A. Puri, Pharmaceutics, 2014, 6, 1–25.
35 M. M. Fretz, A. Høgset, G. A. Koning, W. Jiskoot and
G. Storm, Pharm. Res., 2007, 24, 2040–2047.
Nanoscale Paper























































































36 C.-S. Lee, W. Park, S. Park and K. Na, Biomaterials, 2013,
34, 9227–9236.
37 T. Lajunen, L.-S. Kontturi, L. Vitala, M. Manna,
O. Cramariuc, T. Róg, A. Bunker, T. Laaksonen, T. Vitala,
L. Murtomäki and A. Urtti, Mol. Pharmaceutics, 2016, 13,
2095–2107.
38 L. Feng, L. Cheng, Z. Dong, D. Tao, T. E. Barnhart, W. Cai,
M. Chen and Z. Liu, ACS Nano, 2017, 11, 927–937.
39 C. Komeda, A. Ikeda, J. Kikuchi, N. Ishida-Kitagawa,
H. Tatebe, K. Shiozaki and M. Akiyama, Org. Biomol. Chem.,
2013, 11, 2567–2570.
40 J. Massiot, A. Makky, F. Di Meo, D. Chapron, P. Trouillas
and V. Rosilio, Phys. Chem. Chem. Phys., 2017, 19, 11460–
11473.
41 A. Accardo and G. Morelli, Pept. Sci., 2015, 104, 462–479.
42 J. Y. Hwang, Z. Li and X. J. Loh, RSC Adv., 2016, 6, 70592–
70615.
43 J. M. van den Hoven, S. R. Van Tomme, J. M. Metselaar,
B. Nuijen, J. H. Beijnen and G. Storm, Mol. Pharmaceutics,
2011, 8, 1002–10015.
44 T. A. Theodossis, A. R. Gonçalves, K. Yannakopoulou,
E. Skarpen and K. Berg, Angew. Chem., Int. Ed., 2015, 54,
4885–4889.
45 L. Bourré, F. Giuntini, I. M. Eggleston, C. A. Mosse,
A. J. MacRobert and M. Wilson, Photochem. Photobiol. Sci.,
2010, 9, 1613–1620.
46 M. Sardan, M. Kilinic, R. Genc, A. B. Tekinay and
M. O. Guler, Faraday Discuss., 2013, 166, 269–283.
47 K. J. Oh, S. Barbuto, K. Pitter, J. Morash, L. D. Walensky
and S. J. Korsmeyer, J. Biol. Chem., 2006, 281, 36999–37008.
48 M. S. Mathews, J. W. Blickenstaﬀ, E. C. Shih, G. Zamora,
V. Vo, C. H. Sun, H. Hirschberg and S. I. Madsen,
J. Biomed. Opt., 2012, 17, 058001.
49 V. P. Torchillon, R. Rammohan, V. Weissig and
T. S. Levchenko, Proc. Natl. Acad. Sci. U. S. A., 2001, 98,
8786–8791.
50 M. M. Fretz, G. A. Koning, E. Mastrobattista, W. Jiskoot and
G. Storm, Biochim. Biophys. Acta, 2004, 1665, 48–56.
51 M. M. Fretz and G. Storm, Methods Mol. Biol., 2010, 605,
349–359.
52 H. Gao, Q. Zhang, Z. Yu and Q. He, Curr. Pharm.
Biotechnol., 2014, 15, 210–219.
53 M. B. Hansen, E. van Gaal, I. Minten, G. Storm, J. C. M. van
Hest and D. W. P. M. Löwik, J. Controlled Release, 2012,
164, 87–94.
54 J. Wang, S. Shen, D. Li, C. Zhan, Y. Yuan and X. Yang, Adv.
Funct. Mater., 2018, 28, 1704806.
55 S. Santra, H. Yang, J. T. Stanley, P. H. Holloway,
B. M. Moudgil, G. Walter and R. A. Mericle, Chem.
Commun., 2005, 3144–3146.
56 E. O. Blenke, G. Klasse, H. Merten, A. Plückthun,
E. Mastrobattista and N. I. Martin, J. Controlled Release,
2015, 202, 14–20.
57 B. P. Gray, S. Li and K. C. Brown, Bioconjugate Chem., 2012,
24, 85–96.
58 V. S. Gaware, M. Håkerud, A. Juzeniene, A. Høgset, K. Berg
and M. Másson, Biomacromolecules, 2017, 18, 1108–1126.
59 A. El-Sayed, S. Futaki and H. Harashima, AAPS J., 2008, 11,
13–22.
60 A. Erazo-Oliveras, N. Muthukrishnan, R. Baker, T.-Y. Wang
and J.-P. Pellois, Pharmaceuticals, 2012, 5, 1177–1209.
61 B. A. Martinez de Pinillos, J. H. Woodhams, H. Pye,
R. A. Hamoudi, C. M. Moore and A. J. MacRobert, Cancer
Lett., 2017, 393, 68–75.
62 P. K. Selbo, M. G. Rosenblum, L. H. Cheung, W. Zhang and
K. Berg, PLoS One, 2009, 4, e6991.
Paper Nanoscale
20376 | Nanoscale, 2018, 10, 20366–20376 This journal is © The Royal Society of Chemistry 2018
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
8 
O
ct
ob
er
 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
2/
11
/2
01
8 
3:
05
:1
3 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
